Resurfaced Stabilized Core 3 (RSC3) Protein, Derived Proteins, and DNA Encoding These Proteins: RSC3, RSC3 delta371I, RSC3 delta371I/P363N, RSC3 G367R

Details for these materials may be found in the NIH AIDS Reagent Program Catalog –

Prefusion HPIV F Immunogens and Their Use.

Human parainfluenza virus (hPIV) is an RNA-based paramyxovirus that causes respiratory infections in children and adults. There are four serotypes that can result in a myriad of diseases of the respiratory tract including croup, bronchitis, and pneumonia (Mao et al., 2012). hPIV is a leading cause of respiratory tract infection and hospitalization among children under 5, only surpassed by the respiratory syncytial virus (RSV). Currently, there are limited treatment options and no approved vaccines.

Glycan-masked engineered outer domains of HIV-1 GP120 and Their Use

The VRC01-class of potent, broadly neutralizing antibodies (bnAbs) targets the conserved CD4-binding site (CD4bs) of HIV-1 Env which has been a major target of HIV-vaccine design. The current best priming immunogen to engage the VRC01-class germline precursors is the eOD-GT8 60mer, which elicits VRC01-class precursors in multiple transgenic mouse models. However, a large proportion of the antibodies elicited by eOD-GT8 60mer are non-CD4bs or “off-target” antibodies, undermining its effectiveness in eliciting the VRC01-class bnAb precursors.

Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP as an Intranasal Ebola Vaccine

Ebola virus (EBOV) hemorrhagic fever is one of the most lethal viral infections and lacks a licensed vaccine. EBOV is transmitted by contact with body fluids from infected individuals including droplets or aerosols. Aerosolized EBOV could also be exploited for intentional virus spread. Therefore, vaccines that protect against mucosal and systemic exposure are needed.

Recombinant RSV B1 expressing eGFP as a reporter gene

The inventors have created a reverse genetics system for RSV strain B1 of antigenic subgroup B encoding a replication-competent recombinant RSV that contains a codon-optimized G ORF and expresses enhanced green fluorescence protein (GFP). There are two antigenic subgroups of RSV, subgroups A and B, and most of the available information and reagents are for subgroup A. Immunity against either subgroup has reduced effectiveness in restricting the heterologous subgroup, suggesting that an effective RSV vaccine might need to contain both subgroups.

Substitutions-Modified Prefusion RSV F Proteins and Their Use

The respiratory syncytial virus (RSV) fusion (F) glycoprotein is the primary target of neutralizing antibodies. The F glycoprotein exists in at least two conformations, a meta-stable prefusion state, and an extremely stable postfusion state. Both states share several epitopes targeted by neutralizing antibodies, but it has been demonstrated that the prefusion conformation of F contains at least one epitope not present in the postfusion conformation.

Recombinant HIV-1 Envelope Protein for Vaccine Use

In pursuit of an effective vaccine to end the global HIV-1/AIDS pandemic, researchers at the Vaccine Research Center (“VRC”) continue to study the structure of HIV-1. Recently, these researchers have determined the three-dimensional structure of the HIV-1 Envelope trimeric ectodomain (“Env”), comprised of three gp120 and three gp41 subunits, in its prefusion, mature, closed conformation.

Hybridoma cell lines producing antibodies to RSV NS1

This technology provides a new set of hybridoma cell lines each expressing a single monoclonal antibody against human respiratory syncytial virus (RSV) nonstructural protein 1 (NS1). These antibodies have variously been shown to detect NS1 protein in an enzyme-linked immunosorbent assay (ELISA), Western blot assay, immunofluorescence microscopy of paraformaldehyde-fixed cells, and flow cytometry. The various antibodies can vary in their efficiency in each of these assays.
Subscribe to NIAID